Naturally occuring inhibitors

FXIIIa-blocker Tridegin is a 66 amino acid polypeptide present in the saliva of the giant Amazon leech Haementeria ghilianii. Tridegin is neither a competitive inhibitor nor an unspecific thiol-group blocking agent. The inhibition mechanism is unknown so far. Finney et al. (Biochem. J.1997, 324:797-805) reported an IC50 of about 10 nM for factor XIIIa, whereas Sicker (PhD thesis, 2008) measured an IC50 of 2.5 μM for the recombinant protein.

Using recombinant Tridegin we determined IC50 -values against FXIIIa of 0.4 μM (T036) and 1.8 μM (F001) depending on the assay used (Product No. indicated in brackets). Human TG2 isn’t inhibited by recombinant Tridegin at concentrations up to 10 μM.
Further some microorganism derived unspecific “factor XIIIblockers” with IC50 -values in the micromolar range have been described, e.g. the antifungal antibiotic Cerulenin (Tymiak et al., J. Antibiot. 1993, 46:204-6).

Art. No.
T087 Tridegin
(rec. produced in E. coli, gene derived from Haementeria ghilianii)
200 µg
480 €

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland